Showing 1831-1840 of 2105 results for "".
- CSF Biomarkers of Inflammation Are Predictive of Cognitive Declinehttps://practicalneurology.com/news/csf-biomarkers-of-inflammation-are-predictive-of-cognitive-decline/2470452/Analysis of study results presented at the American Academy of Neurology (AAN) 2024 Annual Meeting demonstrate that cerebrospinal fluid (CSF) inflammatory cytokine levels are predictive of clinically meaningful cognitive decline (CMCD) at 1 year follow up. TGF-β3 and TNFR2 were shown to be t
- UCSF Professor Bruce Ovbiagele, MD Recognized with Scientific Breakthrough Award at AAN 2024https://practicalneurology.com/news/ucsf-professor-bruce-ovbiagele-md-recognized-with-scientific-breakthrough-award-at-aan-2024/2470442/This year, the American Brain Foundation (ABF) awarded Bruce Ovbiagele, MD, MAS, FAAN the annual Scientific Breakthrough Award. Dr Ovbiagele, a Professor of Neurology at University of California (UC) San Francisco and Associate Dean of the San Francisco Veterans Affairs (VA) Healthcare Syste
- Ultrasound-Guided Lumbar Puncture Not Superior to Traditional Landmark-Based Approach According to Study at AAN 2024https://practicalneurology.com/news/ultrasound-guided-lumbar-puncture-not-superior-to-traditional-landmark-based-approach-according-to-study-at-aan-2024/2470441/Ultrasound guidance did not significantly affect the outcomes of lumbar puncture (LP) performed by a single experienced practitioner in the outpatient setting. According to data from the UltraGUD LP clinical trial (NCT03815045), which were presented at the American Academy of Neurology (AAN) 2024
- New Study Examines the Risk of Relapse in Those Discontinuing MS Therapyhttps://practicalneurology.com/news/new-study-examines-the-risk-of-relapse-in-those-discontinuing-ms-therapy/2470432/The discontinuation of high-efficacy therapies (HETs) that impact immune cell trafficking, including Tysabri (natalizumab; Biogen, Cambridge, MA) and Gilenya (fingolimod; Novartis, East Hanover, NJ), in people aged ≥50 years with nonactive multiple sclerosis (MS) was associated with a signific
- Duvyzat Approved by FDA As Treatment for Duchenne Muscular Dystrophyhttps://practicalneurology.com/news/duvyzat-approved-by-fda-as-treatment-for-duchenne-muscular-dystrophy/2470429/Duvyzat (givinostat; Italfarmaco SpA, Milan, Italy), a histone deacetylase (HDAC) inhibitor, was approved by the Food and Drug Administration (FDA) to treat Duchenne muscular dystrophy (DMD) in individuals aged >6 years. This is the first nonsteroidal drug approved to treat DMD. FDA
- Investigational Small Molecule Therapy for Progressive MS Associated with Reduced Serum NfL Levels Compared with Placebohttps://practicalneurology.com/news/vidofludimus-calcium-reduces-serum-nfl-levels-compared-with-placebo-in-those-with-progressive-ms/2470416/According to interim analysis of the CALLIPER clinical trial (NCT05054140), people with progressive multiple sclerosis (PMS) subtypes who were treated with VidoCa (vidofludimus calcium; Immunic, New York, NY) as an oral tablet for 24 weeks showed a significant reduction in serum neurofilament lig
- Barancik Prize Awarded to Sergio E. Baranzini, PhD at ACTRIMS 2024https://practicalneurology.com/news/barancik-prize-awarded-to-sergio-e-baranzini-phd-at-actrims-2024/2470413/This year, the National Multiple Sclerosis Society has awarded Sergio E. Baranzini, PhD the prestigious Barancik Prize for Innovation in Multiple Sclerosis (MS) Research. Professor Baranzini is a geneticist, neuroimmunologist, and data scientist at the University of California, San Francisco (UCS
- Endovascular Thrombectomy Improves Functional Outcomes Long Term in Patients with Large Vessel Occlusion Ischemic Strokehttps://practicalneurology.com/news/endovascular-thrombectomy-improves-functional-outcomes-long-term-in-patients-with-large-vessel-occlusion-ischemic-stroke/2470401/Endovascular thrombectomy (EVT) improved functional outcomes in patients with anterior circulation large vessel occlusion ischemic stroke and large ischemic core at 1 year of follow up, according to long-term results from the SELECT2 clinical trial (NCT03876457). EVT also met secondary outcomes a
- Anticoagulation Therapy Does Not Reduce Risk of Recurrent Stroke Compared with Aspirin in Those with Cryptogenic Stroke and Atrial Cardiopathyhttps://practicalneurology.com/news/anticoagulation-therapy-does-not-reduce-risk-of-recurrent-stroke-compared-with-aspirin-in-those-with-cryptogenic-stroke-and-atrial-cardiopathy/2470399/Treatment with Eliquis (apixaban; Bristol Myers Squibb, New York, NY), an anticoagulant medication, did not significantly reduce the risk of recurrent stroke compared with aspirin therapy in people with cryptogenic stroke and evidence of atrial cardiopathy. The findings of the ARCADIA clinical tr
- Boston Scientific’s Spinal Cord Stimulation Systems Effective at Reducing Back Painhttps://practicalneurology.com/news/boston-scientifics-spinal-cord-stimulation-systems-effective-at-reducing-back-pain/2470387/Using the WaveWriter and WaveWriter Alpha Spinal Cord Stimulation (SCS) Systems (Boston Scientific, Marlborough, MA) resulted in sustained pain relief as treatment for non-surgical back pain (NSBP), according to positive 1-year results from the SOLIS clinical trial (NCT04676022). These findi